Literature DB >> 6238068

Weight gain. A side-effect of tricyclic antidepressants.

G H Berken, D O Weinstein, W C Stern.   

Abstract

Body weight and appetite were evaluated in 40 depressed outpatients from a private psychiatric practice who were receiving low-modest doses of tricyclic antidepressants. Amitriptyline (maximum of 150 mg/day), nortriptyline (maximum of 50 mg/day), and imipramine (maximum of 80 mg/day) were given for an average of 6 months of treatment. There was a mean weight increase of 1.3-2.9 lbs/month, which led to an average total weight gain of 3-16 lbs, depending on drug, dose and duration. These weight increases were linear over time and were accompanied by marked increases in the preference for sweets. Ultimately, excessive weight gain was the most common cause of discontinuation of treatment, occurring in one-half of the patients. Significant weight loss occurred upon discontinuation of drug. These findings show that chronic administration of low-modest doses of tricyclic antidepressants frequently cause considerable weight gain and can significantly interfere with the ability to provide long-term maintenance therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6238068     DOI: 10.1016/0165-0327(84)90031-4

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  26 in total

Review 1.  Obesogens, stem cells and the developmental programming of obesity.

Authors:  A Janesick; B Blumberg
Journal:  Int J Androl       Date:  2012-02-28

Review 2.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

3.  Observational study of the impact of short-term duloxetine treatment on body weight in patients with major depressive disorder: a taiwanese perspective.

Authors:  Chien-Han Lai
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  Psychotropic-induced weight gain and potential pharmacologic treatment strategies.

Authors:  Barbara L Gracious; Ashley E Meyer
Journal:  Psychiatry (Edgmont)       Date:  2005-01

Review 5.  Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implications.

Authors:  Yvonne M Ulrich-Lai; Karen K Ryan
Journal:  Cell Metab       Date:  2014-03-13       Impact factor: 27.287

Review 6.  Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.

Authors:  B H Guze
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

7.  Desvenlafaxine and weight change in major depressive disorder.

Authors:  Karen A Tourian; Claire Leurent; Jay Graepel; Philip T Ninan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 8.  Endocrine disrupting chemicals and the developmental programming of adipogenesis and obesity.

Authors:  Amanda Janesick; Bruce Blumberg
Journal:  Birth Defects Res C Embryo Today       Date:  2011-03

Review 9.  Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.

Authors:  S M Cheer; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 10.  Obesity in America: implications for clinical and health psychologists.

Authors:  Melanie K Bean; Karen Stewart; Mary Ellen Olbrisch
Journal:  J Clin Psychol Med Settings       Date:  2008-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.